Gen-Plus develops innovative formulation concepts and new technologies for the pharmaceutical industry. Self-described as licensed for GMP manufacturing of clinical trial products from Phase I to IV.

Gen-Plus

biosyn Arzneimittel GmbH is involved in the pharmaceutical and biotech sectors, specializing in trace elements, particularly high-dose selenium injections, and operates unique GMP-active ingredient manufacturing plants.

biosyn Arzneimittel GmbH

Gen-Plus GmbH &amp; Co. KG | 1,019 followers on LinkedIn. Pharma Innovation for the Next Generation | Legal notice: Our legal notice can be accessed by clicking on the &quot;More Information&quot; button and at https://www.gen-plus.de/impressum-agb.

Gen-Plus is a small medium-sized, privately owned company. Its aim is to discover innovations for contract partners.

Chemiker

Cedrique Temoka

Senior Director Business Development North America at Conscio Group, Scientific Advisor at Gen-Plus

Karin Cooke, PhD

PhD | Business Development Director & Scientist - Pharmaceuticals, CDMO/CRO

Lia Martinez-Montero

Dr. Nur Alam

Gen-Plus GmbH & Co. KG

Farewell Milan 🔛 Welcome Frankfurt! Together with our group companies — QUINTA-ANALYTICA , Gen-Plus GmbH & Co. KG , EL Labs , LVA GmbH , Reference Analytics GmbH and our strategic partner Kiel Laboratories, Inc. — we want to thank you for being part of this incredible journey with us at CPHI 2024. 🔝 We’re already looking forward to seeing you at CPHI 2025 in Frankfurt, Germany. 🔜 Save the date, and we’ll see you soon! #CPHI2024 #CPHI2025 #PharmaceuticalIndustry #Biosimilars #PharmaPartnerships #InnovationInPharma #ConscioGroup #QuintaAnalytica #GenPlus #LVA #ELLabs #referenceanalytics

Conscio Group

👋 Conscio Group is live at CPHI Milan! We’re thrilled to connect with industry leaders and innovators at CPHI 2024. At the heart of our showcase? Our cutting-edge analytical and clinical testing services designed to help you navigate regulatory pathways and bring high-quality treatments to market faster. Stop by our booth #22G4 to learn how we can support your product development journey with tailored, high-impact solutions. 💬 Can’t make it? Visit our web page to learn more: www.consciogroup.com #CPHI2024 #Biosimilars #PharmaInnovation #ClinicalTrials #ConscioGroup

🌟 We’re heading to CPHI Milan 2024! Conscio Group is excited to be part of CPHI Milan, where the world’s pharmaceutical leaders gather to shape the future of healthcare. We’ll be showcasing our expert biosimilar services, demonstrating how we accelerate success with precision, speed, and innovation. ✔ If you're attending, be sure to visit us and discover how our tailored solutions — including analytical method development, clinical trials, bioanalytical testing, and quality control — can support your biosimilar journey. ❗ Not attending? Contact us today and speak to one of our experts about our services: https://lnkd.in/eaTEYXZA Also, check out our new landing page focused on biosimilar analysis: https://lnkd.in/ehdJHCKY #CPHI2024 #Biosimilars #PharmaInnovation #ClinicalTrials #BioanalyticalTesting #ConscioGroup

Visit Conscio Group at CPHI 2024 in Milan! 🌍 Join us at booth 22G4 in the Integrated Pharma Hall, where we'll showcase our expertise in drug development, including innovative formulations, pharmaceutical research, analytical solutions for pharmaceuticals and biologics, and clinical development such as trials and bioanalysis. 💊 Discover how we can help bring your concept to product. Alongside our companies: QUINTA-ANALYTICA , Gen-Plus GmbH & Co. KG , Reference Analytics GmbH , EL Labs , LVA GmbH , you can also meet our USA based strategic partner, Kiel Laboratories, Inc. , a specialist in the 505(b)(2) process. 📅 Don’t wait and book a time slot with your established business representative or send your meeting request to info@consciogroup.com .

☀ Summer is not over yet, but we are already gearing up for another major pharma event – the 14th American DDF Summit (Drug Delivery & Formulation) , taking place from September 16 to 17 in San Diego, California. 💠 Dr. Karin Cooke, PhD , Director of Business Development for North America at Conscio Pharma, will be available to discuss formulation development, GMP manufacturing, and drug delivery systems. With her expertise, she can address your queries and offer tailored solutions in the field of difficult-to-formulate drugs and advanced technologies such as 2D/3D printing and transdermal delivery systems and many more. 💠 If you are attending this event, don't miss the opportunity to connect with her and book a meeting by emailing karin.cooke@consciogroup.com or visit our webpage www.consciogroup.com to discover our wide portfolio of solutions for the pharmaceutical industry.

Do you know what solid oral dosage forms are made of and what their main ingredients are for? ◽ Solid oral dosage forms, such as tablets and capsules, consist of various components, each with a specific function to ensure proper delivery and efficacy of the active ingredients. ◽ Achieving perfect formulation involves understanding these ingredients and their roles. This knowledge is crucial for formulation development, analytical measurements and clinical trials. By leveraging our expertise, we help ensure your products are safe, effective, and of the highest quality. Our innovative approaches and comprehensive analyses can save you time and resources, bringing your products to market faster. Embrace the science behind effective pharmaceuticals with our expert support.

📢 Are you a biotech enthusiast seeking cutting-edge solutions for your project? 👉 Join Conscio Group at BayOConnect 2024 in Munich on July 2-3! Meet Lia Martinez-Montero , BD Director of Conscio Pharma, and discover our comprehensive services for biosimilars and biologics. From precise analytics and clinical trials to batch release, Conscio Group offers full-spectrum support for your pharmaceutical needs. Whether you're bringing a new product to market or advancing your research, we're here to support your next breakthrough.

Succesful Day 1 at the #DrugDeliverySummit in Frankfurt!! Top innovative presentations and insightful discussions during the networking session! Thank you for giving us the opportunity to present one of most innovative case studies. Reach out to Bernd Sterner or to Lia Martinez-Montero for additional information!

📣 Bernd Sterner, Head of R&D at Gen-Plus GmbH & Co. KG , part of the Conscio Group , will be presenting at the European Drug Delivery Summit 2024 in Frankfurt on June 24-25. Bernd's presentation on "2D Printing Technology for Oral Drug Delivery to Premature Infants" will cover: 🔺 Neonatal Care and Precision Medicine: How 2D printing is revolutionizing treatments for premature infants. 🔺 Hydrocortisone Ink Manufacturing: Insights into developing stable and effective drug formulations for orodispersible films. 🔺 Future Directions: Latest results and future potential of hydrocortisone orodispersible films. Lia Martinez-Montero , BD Director of Conscio Pharma, will also be available to discuss Conscio's comprehensive solutions and innovations in the pharmaceutical industry. 📢 Don’t miss this opportunity to explore the latest advancements in neonatal care and drug delivery technology at the summit. Discover how Conscio is leading the way in pharmaceutical innovation.

Metric
Company Name	Gen-Plus	biosyn Arzneimittel GmbH
Symbol
MSH ID	DE:GEN-PLUS	DE:BIOSYN
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Pharmaceuticals
Country	DE	DE
Stage
Employee Count
Website	gen-plus.de	biosyn.de
LinkedIn	gen-plus	biosyn-arzneimittel-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GEN-

DE:GEN-PLUS

Gen-Plus

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue